// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Comparison of methods for interpreting bronchodilator response (BDR) in children

Stephanie Rees - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study

Leonardo Fabbri - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Investigation of shortened lung clearance index (LCI) in the Bronch-UK Clinimetrics study.

Katherine O'Neill - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Mona Bafadhel - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

budesonide + formoterol fuma

Identification of pulmonary treatable traits in a real-life setting

Jodie Simpson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Methadone hydrochloride

GOLD ABCD assessment tool: Comparison of 2013 and 2017 classifications in the UK Clinical Practice Research Datalink (CPRD)

Alexander Mathioudakis - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Do patients on NIV change their NIV use on nights when they have oximetry?

Paul Plant - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Baseline symptom burden and dual bronchodilator response in the FLAME study

Alexander Mackay - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

salmeterol + fluticasone

Perceptions of the role of the respiratory Clinical Research Nurse

Katherine Huband - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Dyspnoea perception and FEV1 decline during Sputum Induction in Healthy Controls and COPD patients

Pedro Rodrigues - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Wide variation in practices for measuring respiratory rate in children

Will Daw - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Is 'take-out' allergen detectable in laboratory animal facilities?

Johanna Feary - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar microlithiasis

N/A

Critical aspects of Spontaneous Pneumothorax management in secondary care

Michael Mather - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Primary spontaneous pneumothorax

N/A

COPA syndrome restricted to life-threatening alveolar hemorrhages: clinical, pathological, molecular and biological characterization

Nadia Nathan - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon

Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study

Suhani Patel - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Vitamin-D deficiency & anaemia in patients with acute exacerbations of COPD (AECOPD); morbidity & mortality.

Niamh Cafferky - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Vitamin D deficiency

Ergocalciferol

Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge

Massimo Corradi - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

SK1211

Accuracy of built-in software for the detection of residual apneic events occurring during non-invasive ventilation

Elena Lindemann - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Evaluation of a bespoke and innovative model of care to reduce emergency admissions for community acquired pneumonia

Onnor Hampson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessing the financial impact of pulmonary hypertension: a survey by the UK Pulmonary Hypertension Association (PHA-UK)

Iain Armstrong - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Copyright © 2026. QuantiNova All rights reserved